This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
BMC Cancer Open Access 16 October 2008
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vardiman J-W, Harris N-L, Brunning R-D . The world health classification (WHO) of myeloid neoplasms. Blood 2002; 100: 2292–2302.
Elliott MA . Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol 2006; 19: 571–593.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British cooperative leukaemia group. Br J Haematol 1994; 84: 746–754.
Germing U, Gattermann N, Minning H, Heyll A, Aul C . Problems in the classification of CMML – dysplastic versus proliferative type. Leuk Res 1998; 22: 871–878.
Nösslinger T, Reisner R, Gruner H, Tuchler H, Nowotny H, Pittermann E et al. Dysplastic versus proliferative CMML – a retrospective analysis of 91 patients from a single institution. Leuk Res 2001; 25: 741–747.
Gonzalez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I . Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002; 26: 821–824.
Onida F . Pronostics factors in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.
Lelièvre H, Cervera N, Finetti P, Delhommeau F, Vainchenker W, Bertucci F et al. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators. Leukemia 2006; 20: 1885–1888.
Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101: 4988–5006.
Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567–6572.
Acknowledgements
This work was supported by Inserm, Institut Paoli-Calmettes and grants from Institut National du Cancer (Cancéropôle PACA/IDF ACI2005, PHRC no. 24-33 2005). We thank C Chabannon for the biobanking.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Gelsi-Boyer, V., Cervera, N., Bertucci, F. et al. Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. Leukemia 21, 2359–2362 (2007). https://doi.org/10.1038/sj.leu.2404805
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404805
This article is cited by
-
Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML)
Leukemia (2015)
-
Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies
Leukemia (2010)
-
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
BMC Cancer (2008)